Compound Evidence File
#EC-2026-0781
Lipo-B 216mg
Filed under Injectable Oils. The bureau holds 150 laboratory returns for this compound from 58 distinct subjects. Scores below are per-subject aggregates; open a subject row for the underlying evidence.
Cross-Index
Subjects Shipping This Compound
58 SUBJECTS| Subject | Grade | Samples | Mean | Min | Max | First seen | Last seen |
|---|---|---|---|---|---|---|---|
| Tianjin Finder Chemical TFCCASE #VI-2026-0693 | A | 6 | 10.0 | 9.9 | 10.0 | 14 Nov 2025 | 16 Apr 2026 |
| JEEP PeptidesCASE #VI-2026-0457 | A | 4 | 10.0 | 9.9 | 10.0 | 15 Feb 2026 | 9 Jul 2026 |
| Hubei JianxiangCASE #VI-2026-0048 | A | 4 | 10.0 | 9.9 | 10.0 | 26 Nov 2025 | 25 Jun 2026 |
| Chinese Peptide CompanyCASE #VI-2026-0184 | A | 4 | 10.0 | 10.0 | 10.0 | 22 Dec 2025 | 18 May 2026 |
| Hybio PharmaceuticalCASE #VI-2026-0065 | A | 4 | 10.0 | 9.9 | 10.0 | 10 Jan 2026 | 11 Jun 2026 |
| Flourishglobal PeptideCASE #VI-2026-0630 | A | 3 | 10.0 | 9.9 | 10.0 | 23 Nov 2025 | 26 Jun 2026 |
| PolyPeptide GroupCASE #VI-2026-0143 | A | 3 | 10.0 | 9.9 | 10.0 | 8 Jul 2026 | 26 Jul 2026 |
| Shanghai ERP BiotechnologyCASE #VI-2026-0936 | A | 2 | 10.0 | 10.0 | 10.0 | 2 Jan 2026 | 7 Apr 2026 |
| Shanghai Wibson BiotechnologyCASE #VI-2026-0379 | A | 2 | 10.0 | 10.0 | 10.0 | 12 Jun 2026 | 10 Jul 2026 |
| SinoPepCASE #VI-2026-0387 | A | 2 | 10.0 | 10.0 | 10.0 | 27 Mar 2026 | 2 Jul 2026 |
| The Naughty NeedleCASE #VI-2026-0432 | X | 1 | 10.0 | 10.0 | 10.0 | 25 Apr 2025 | 25 Apr 2025 |
| HomopeptideCASE #VI-2026-0760 | A | 6 | 9.9 | 9.9 | 9.9 | 25 May 2026 | 25 May 2026 |
| QYAOBIOCASE #VI-2026-0861 | A | 4 | 9.9 | 9.9 | 10.0 | 17 May 2026 | 6 Jul 2026 |
| Kerui PeptidesCASE #VI-2026-0626 | A | 4 | 9.9 | 9.9 | 10.0 | 18 Mar 2026 | 18 Jun 2026 |
| WuXi TIDESCASE #VI-2026-0335 | A | 4 | 9.9 | 9.9 | 10.0 | 4 Apr 2026 | 21 Jun 2026 |
| Thermo Fisher ScientificCASE #VI-2026-0142 | A | 4 | 9.9 | 9.9 | 10.0 | 23 Dec 2025 | 16 Jul 2026 |
| AsymchemCASE #VI-2026-0091 | A | 4 | 9.9 | 9.9 | 10.0 | 12 Apr 2026 | 13 Aug 2026 |
| Sangon BioCASE #VI-2026-0671 | A | 3 | 9.9 | 9.9 | 9.9 | 21 Feb 2026 | 5 Jul 2026 |
| Mokemei BiotechnologyCASE #VI-2026-0540 | A | 3 | 9.9 | 9.9 | 9.9 | 28 Jan 2026 | 13 Jul 2026 |
| BachemCASE #VI-2026-0314 | A | 2 | 9.9 | 9.9 | 10.0 | 3 Jul 2026 | 11 Jul 2026 |
| Shanghai Sigma AudleyCASE #VI-2026-0505 | A | 2 | 9.9 | 9.9 | 10.0 | 6 Jun 2026 | 12 Jul 2026 |
| GenScript PeptidesCASE #VI-2026-0860 | A | 2 | 9.9 | 9.9 | 10.0 | 21 May 2026 | 12 Jun 2026 |
| Sigma-AldrichCASE #VI-2026-0829 | A | 2 | 9.9 | 9.9 | 9.9 | 1 Jul 2026 | 20 Jul 2026 |
| AmbioPharmCASE #VI-2026-0177 | A | 2 | 9.9 | 9.9 | 9.9 | 15 Jul 2026 | 13 Aug 2026 |
| Bulk Peptide WholesaleCASE #VI-2026-0319 | X | 1 | 9.7 | 9.7 | 9.7 | 20 Jun 2025 | 20 Jun 2025 |
| ZhuoYan labCASE #VI-2026-0902 | X | 2 | 8.9 | 8.8 | 9.0 | 6 May 2025 | 20 May 2026 |
| Anlv BiotechnologyCASE #VI-2026-0110 | X | 1 | 8.9 | 8.9 | 8.9 | 11 Jun 2025 | 11 Jun 2025 |
| NUPEPS PeptidesCASE #VI-2026-0896 | X | 1 | 8.9 | 8.9 | 8.9 | 3 Jul 2025 | 3 Jul 2025 |
| Wuhan Wansheng Bio (WWB)CASE #VI-2026-0594 | A | 2 | 8.8 | 8.7 | 8.8 | 23 May 2026 | 23 May 2026 |
| Shanghai Sigma Audley SSACASE #VI-2026-0486 | A | 2 | 8.7 | 7.4 | 10.0 | 21 May 2026 | 21 May 2026 |
| Nantong Guangyuan Chemical GYCCASE #VI-2026-0284 | A | 8 | 8.5 | 6.0 | 9.9 | 21 May 2026 | 21 May 2026 |
| Qingdao Sigma Chemical QSCCASE #VI-2026-0538 | A | 7 | 8.2 | 7.3 | 8.8 | 23 May 2026 | 23 May 2026 |
| Bfflist AMOCASE #VI-2026-0678 | X | 6 | 8.0 | 6.9 | 9.3 | 25 Apr 2025 | 19 Jan 2026 |
| SRY LabsCASE #VI-2026-0657 | X | 2 | 7.8 | 7.7 | 7.8 | 2 Apr 2025 | 24 May 2026 |
| Verified PeptidesCASE #VI-2026-0407 | X | 2 | 7.6 | 6.3 | 8.8 | 9 Jun 2025 | 19 Jan 2026 |
| Glbiochem (Shanghai)CASE #VI-2026-0704 | A | 2 | 7.5 | 7.3 | 7.8 | 24 May 2026 | 24 May 2026 |
| Lisa BiopeptideCASE #VI-2026-0131 | X | 1 | 7.5 | 7.5 | 7.5 | 21 May 2025 | 21 May 2025 |
| Glamgurcraft Innovations Foreign TradeCASE #VI-2026-0348 | X | 1 | 7.5 | 7.5 | 7.5 | 8 Jul 2025 | 8 Jul 2025 |
| Biolongevity LabsCASE #VI-2026-0442 | X | 1 | 7.3 | 7.3 | 7.3 | 25 Apr 2025 | 25 Apr 2025 |
| Huayi BiotechnologyCASE #VI-2026-0243 | X | 1 | 7.2 | 7.2 | 7.2 | 27 Feb 2025 | 27 Feb 2025 |
| NexaphCASE #VI-2026-0944 | X | 9 | 7.1 | 5.5 | 10.0 | 20 Jun 2025 | 21 May 2026 |
| Pure Tested PeptidesCASE #VI-2026-0225 | X | 1 | 6.9 | 6.9 | 6.9 | 16 Mar 2025 | 16 Mar 2025 |
| Welon Peptide SolutionsCASE #VI-2026-0478 | X | 1 | 6.8 | 6.8 | 6.8 | 28 Mar 2025 | 28 Mar 2025 |
| YimeiCASE #VI-2026-0081 | X | 3 | 6.4 | 2.9 | 8.5 | 28 Mar 2025 | 24 May 2026 |
| Polaris PeptidesCASE #VI-2026-0839 | X | 1 | 6.2 | 6.2 | 6.2 | 24 Apr 2025 | 24 Apr 2025 |
| Zen PeptidesCASE #VI-2026-0940 | X | 1 | 5.9 | 5.9 | 5.9 | 2 Apr 2025 | 2 Apr 2025 |
| Hebei Rimao TechnologyCASE #VI-2026-0529 | X | 2 | 5.8 | 5.2 | 6.3 | 13 Feb 2025 | 24 May 2026 |
| Shanghai BaojuCASE #VI-2026-0233 | X | 1 | 5.7 | 5.7 | 5.7 | 13 Feb 2025 | 13 Feb 2025 |
| Xingruida XDRCASE #VI-2026-0898 | X | 2 | 5.2 | 4.7 | 5.8 | 2 Jul 2025 | 23 May 2026 |
| Pharma Grade PeptidesCASE #VI-2026-0208 | X | 1 | 5.2 | 5.2 | 5.2 | 3 Jun 2025 | 3 Jun 2025 |
| LN PeptidesCASE #VI-2026-0781 | X | 2 | 4.8 | 3.6 | 6.0 | 24 Apr 2025 | 23 May 2026 |
| LipeptidesCASE #VI-2026-0863 | X | 1 | 4.8 | 4.8 | 4.8 | 20 Jun 2025 | 20 Jun 2025 |
| Loti LabsCASE #VI-2026-0171 | X | 3 | 4.7 | 3.5 | 7.0 | 11 Jun 2025 | 17 May 2026 |
| Amino AsylumCASE #VI-2026-0828 | X | 1 | 4.7 | 4.7 | 4.7 | 11 Jun 2025 | 11 Jun 2025 |
| DeuschemCASE #VI-2026-0004 | X | 1 | 4.2 | 4.2 | 4.2 | 9 Jun 2025 | 9 Jun 2025 |
| Suaway Lab ResearchCASE #VI-2026-0488 | X | 1 | 2.1 | 2.1 | 2.1 | 17 Dec 2024 | 17 Dec 2024 |
| SubQ SocietyCASE #VI-2026-0716 | X | 1 | 1.0 | 1.0 | 1.0 | 7 May 2025 | 7 May 2025 |
| Peptide ArkCASE #VI-2026-0350 | X | 1 | 0.0 | 0.0 | 0.0 | 2 Jul 2025 | 2 Jul 2025 |
Open any subject to view the batch-level evidence for Lipo-B 216mg alone.